'Groundbreaking Option' Approved for Rectal Cancer
(MedPage Today) -- The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.